Novel thienylacylhydrazone derivatives inhibit platelet aggregation through cyclic nucleotides modulation and thromboxane A2 synthesis inhibition

European Journal of Pharmacology

Volumn 638, Issue 1-3, 2010, Pages 5-12

  Brito, Fernanda C F ^a,b   Kummerle, Arthur E ^a   Lugnier, Claire ^c   Fraga, Carlos A M ^a   Barreiro, Eliezer J ^a   Miranda s, Ana L P ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^c CNRS   (France)

Author keywords

Cyclic nucleotide; Phosphodiesterase; Platelet aggregation inhibitor; Thienylacylhydrazone derivative

Indexed keywords

(2 THIENYLIDENE) 3,4 METHYLENEDIOXYBENZOYLHYDRAZINE; (5 BROMO 2 THIENYLIDENE) 3,4 METHYLENEDIOXYBEZOYLHYDRAZINE; (5 METHYL 2 THIENYLIDENE) 3,4 METHYLENEDIOXYBENZOYLHYDRAZINE; 15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ANTITHROMBOCYTIC AGENT; ARACHIDONIC ACID; COLLAGEN; CYCLIC GMP; CYCLIC NUCLEOTIDE; HYDRAZONE DERIVATIVE; KT 5720; LASSBIO 294; LASSBIO 785; LASSBIO 786; LASSBIO 787; LASSBIO 788; LASSBIO 789; N (2 THIENYLIDENE) 3,4 METHYLENEDIOXYBENZOYLHYDRAZINE; N BENZYL(2 THIENYLIDENE) 3,4 METHYLENEDIOXYBENZOYLHYDRAZINE; N METHYL(2 THIENYLIDENE) 3,4 METHYLENEDIOXYBENZOYLHYDRAZINE; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE; THROMBIN; THROMBOXANE A2; UNCLASSIFIED DRUG; THIOPHENE DERIVATIVE;

ANIMAL EXPERIMENT; ANTICOAGULATION; ARTICLE; BLEEDING TIME; CELL STIMULATION; CONTROLLED STUDY; DRUG POTENCY; DRUG STRUCTURE; ENZYME INHIBITION; MOUSE; NONHUMAN; PLASMA; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RABBIT; THROMBOCYTE; THROMBOCYTE AGGREGATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CHEMICAL STRUCTURE; DRUG EFFECTS; FEMALE; HUMAN; MALE; METABOLISM; STRUCTURE ACTIVITY RELATION;

ANIMALS; ARACHIDONIC ACID; BLEEDING TIME; BLOOD PLATELETS; COLLAGEN; FEMALE; HUMANS; HYDRAZONES; MALE; MICE; MOLECULAR STRUCTURE; NUCLEOTIDES, CYCLIC; PHOSPHORIC DIESTER HYDROLASES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RABBITS; STRUCTURE-ACTIVITY RELATIONSHIP; THIOPHENES; THROMBIN; THROMBOXANE A2;

EID: 77953500317     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.04.003     Document Type: Article

References (36)

1. Barreiro E.J. Estratégia de simplificação molecular no planejamento racional de fármacos: a descoberta de novo agente cardioativo. Quím. Nova 2002, 25:1172-1180.
2. Born G.V., Cross M.J. The aggregation of blood platelets. J. Physiol. 1963, 168:178-195.
3. Brideau C., Kargman S., Liu S., Dallob A.L., Ehrich E.W., Rodger I.W., Chan C.C. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm. Res. 1996, 45:68-74.
4. Cardinal D.C., Flower R.J. The electronic aggregometer: a novel device for assessing platelet behavior in blood. J. Pharmacol. Meth. 1980, 3:135-158.
5. Cazenave J.P., Benveniste J., Mustard F.J. Aggregation of rabbit platelets by platelet-activating factor is independent of release reaction and the arachidonate pathway and inhibited by membrane-active drugs. Lab. Invest. 1979, 41:275-285.
6. Chackalamannil S., Xia Y., Greenlee W.J., Clasby M., Doller D. Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents. J. Med. Chem. 2005, 48:5884-5887.
7. Chew D.P., Bhatt D.L., Topol E.J. Oral glycoprotein IIb/IIIa inhibitors. Why don't they work?. Am. J. Cardiovasc. Drugs 2001, 1:421-428.
8. Clutton P., Folts J., Freedman J.E. Pharmacological control of platelet function. Pharmacol. Res. 2001, 44:255-264.
9. Csomor K., Karpati E. Effect of vintoperol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 1994, 44:36-40.
10. Dickinson N.T., Jang E.K., Haslam R.J. Activation of cGMP-stimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets: effects on platelet aggregation. Biochem. J. 1997, 323:371-377.
11. Dogne J.M., Rolin S., de Leval X., Benoit P., Neven P., Delarge J., Kolh P., Damas J., David J.L., Masereel B. Pharmacology of the thromboxane receptor antagonist and thromboxane synthase inhibitor BM- 531. Cardiovasc. Drug Rev. 2001, 19:87-96.
12. Duarte C.M., Fraga C.A.M., Barreiro E.J. Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev. Med. Chem. 2007, 7:1108-1119.
13. Dunkern T.R., Hatzelmann A. The effect of sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5. Cell Sign 2005, 17:331-339.
14. Feijge M.A.H., Ansink K., Vanschoonbeek K., Heemskerk J.W.M. Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3. Biochem. Pharmacol. 2004, 67:1559-1567.
15. Feinman R.D., Lubowsky J., Charo I., Zabinski M.P. The lumi-aggregometer: a new instrument for simultaneous measurement of secretion and aggregation by platelets. J. Lab. Clin. Med. 1977, 90:125-129.
16. Fraga C.A.M., Barreiro E.J. Medicinal chemistry of N-acylhydrazones: new lead-compounds of analgesic, antiinflammatory and antithrombotic drugs. Curr. Med. Chem. 2006, 13:167-198.
17. Gonzalez-Serratos H., Chang R., Pereira E.F., Castro N.G., Aracava Y., Melo P.A., Lima P.C., Fraga C.A.M., Barreiro E.J., Albuquerque E.X. A novel thienylhydrazone, (2-thienylidene) 3, 4-methylenedioxybenzoylhydrazine, increases inotropism and decreases fatigue of skeletal muscle. J. Pharmacol. Exp. Ther. 2001, 299:558-566.
18. Jackson S.P., Schoenwaelder S.M. Antiplatelet therapy: in search of the "magic bullet". Nat. Rev. Drug Discov. 2003, 2:775-789.
19. Katori M. Thrombus models and mechanisms of action of antiplatelet drugs. Nippon Yakurigaku Zasshi 1992, 100:271-277.
20. Li Z., Xi X., Gu M. A stimulatory role for cGMP-dependent protein kinase in platelet activation. Cell 2003, 112:77-86.
21. Li Z., Zhang G., Marjanovic J.A., Ruan C., Du X. A platelet secretion pathway mediated by cGMP-dependent protein kinase. J. Biol. Chem. 2004, 279:42469-42475.
22. Liao C.H., Tzeng C.C., Teng C.M. Cyclic AMP and cyclic GMP phosphodiesterase inhibition by an antiplatelet agent, 6-[(3-methylene-2-oxo-5-phenyl-5-tetrahydrofuranyl)methoxy)quinol inone (CCT-62). Eur. J. Pharmacol. 1998, 349:107-114.
23. Lugnier C., Komas N. Modulation of vascular cyclic nucleotide phosphodiesterases by cyclic GMP: role in vasodilatation. Eur. Heart J. 1993, 14:141-148.
24. Lugnier C., Schoeffter P., Le Bec A., Strouthou E., Stoclet J.C. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem. Pharmacol. 1986, 35:1743-1751.
25. McGregor L., Martin J., McGregor J.L. Platelet-leukocyte aggregates and derived microparticles in inflammation, vascular remodelling and thrombosis. Front. Biosci. 2006, 11:830-837.
26. Miranda A.L.P., Lima P.C., Tributino J.L.M., Melo P.A., Fernandes P.D. Anti-inflammatory, analgesic and antiplatelet properties of LASSBio 294, a new thienylacylhydrazone derivative. 6ème Congr. Ann. Soc. Fr. Pharmacol. 2002, 62.
27. Murayama T., Kajiyama Y., Nomura Y. Histamine-stimulated and GTP-binding proteins-mediated phospholipase A2 activation in rabbit platelets. J. Biol. Chem. 1990, 265:4290-4295.
28. Needleman P., Turk J., Jakschik B.A., Morrison A.R., Lefkowith J.B. Arachidonic acid metabolism. Annu. Rev. Biochem. 1986, 55:69-102.
29. Piaz V.D., Vergelli C., Giovannoni M.P., Scheideler M.A., Petrone G. 4-Amino-3(2H)-pyridazinones bearing arylpiperazinylalkyl groups and related compounds: synthesis and antinociceptive activity. Farmaco 2003, 58:1063-1071.
30. Roger S., Pawlowski M., Habib A., Jandrot-Perrus M., Rosa J.-P. Costimulation of the Gi-coupled ADP receptor and the Gq-coupled TXA2 receptor is required for ERK2 activation in collagen-induced platelet aggregation. FEBS Lett. 2003, 556:227-235.
31. Schwarz U.R., Walter U., Eigenthaler M. Taming platelets with cyclic nucleotides. Biochem. Pharmacol. 2001, 62:1153-1161.
32. Silva C.L., Noël F., Barreiro E.J. Cyclic GMP-dependent vasodilatory properties of LASSBio 294 in rat aorta. Br. J. Pharmacol. 2002, 135:293-298.
33. Silva A.G., Zapata-Sudo G., Kummerle A.E., Fraga C.A., Barreiro E.J., Sudo R.T. Synthesis and vasodilatory activity of new N-acylhydrazone derivatives, designed as LASSBio-294 analogues. Bioorg. Med. Chem. 2005, 13:3431-3437.
34. Sudo R.T., Zapata-Sudo G., Barreiro E.J. The new compound, LASSBio 294, increases the contractility of intact and saponin-skinned cardiac muscle from Wistar rats. Br. J. Pharmacol. 2001, 134:603-613.
35. Tendera M., Wojakowski W. Role of antiplatelet drugs in the prevention of cardiovascular events. Thromb. Res. 2003, 110:355-359.
36. Van der Meijden P.E., Feijge M.A., Giesen P.L., Huijberts M., van Raak L.P. Platelet P2Y12 receptors enhance signalling towards procoagulant activity and thrombin generation. A study with healthy subjects and patients at thrombotic risk. Thromb. Haemost. 2005, 93:1128-1136.